REFERENCES

1. Jones JM. LGBTQ+ Identification in U.S. Rises to 9.3%. Gallup. Available from: https://news.gallup.com/poll/656708/lgbtq-identification-rises.aspx [Last accessed on 30 Apr 2026].

2. Endocrine society. Dosing standards for pubertal suppression and sex steroid hormones in transgender youth. 2020. Available from: https://www.endocrine.org/-/media/endocrine/files/practice/gender_dosing_standards_transgender_youth.pdf [Last accessed on 22 Apr 2026].

3. Rosser T, Packer RJ. Neurofibromas in children with neurofibromatosis 1. J Child Neurol. 2002;17:585-91.

4. Dagalakis U, Lodish M, Dombi E, et al. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J Pediatr. 2014;164:620-4.

5. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:3869-903.

6. Deutsch MB. Overview of masculinizing hormone therapy. UCSF Transgender Care & Treatment Guidelines. Available from: https://transcare.ucsf.edu/guidelines/masculinizing-therapy [Last accessed on 22 Apr 2026].

7. Pennanen P, Peltonen S, Kallionpää RA, Peltonen J. The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1^+/- or NF1^-/- genotype derived from human cutaneous neurofibromas. Mol Cell Biochem. 2018;444:27-33.

8. Bubley JA, Yeung H, Cole E, Amin M, Parker D, Arbiser JL. Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone. JAAD Case Rep. 2020;6:1101-3.

9. Herman JL, Flores AR, O’Neill KK. How many adults and youth identify as transgender in the United States? The Williams Institute, UCLA School of Law. 2022. Available from: https://williamsinstitute.law.ucla.edu/wp-content/uploads/Trans-Pop-Update-Jun-2022.pdf [Last accessed on 22 Apr 2026].